Renowned Pharma and Biotech Development Leader, Dr. Andreas Wallnöfer, is named to Optigo Biotherapeutics’ Board of Directors as the company advances to IND-enabling studies VANCOUVER, British ...
VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Optigo Biotherapeutics (“Optigo”), an ophthalmology company pioneering next-gen treatments for retinal diseases, today announced that Dr.
VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Optigo Biotherapeutics ("Optigo"), an ophthalmology company pioneering next-gen treatments for retinal diseases, today announced that Dr.
“Andreas is exactly the strategic leader and industry veteran we were looking for,” said Dr. Henning Afflerbach, Chair of the Board of Optigo. “His singular blend of operational experience — from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results